7.61
+0.36(+4.97%)
Currency In USD
| Previous Close | 7.25 |
| Open | 7.36 |
| Day High | 7.77 |
| Day Low | 7.31 |
| 52-Week High | 15.74 |
| 52-Week Low | 5.6 |
| Volume | 15.28M |
| Average Volume | 14.98M |
| Market Cap | 2.92B |
| PE | -4.94 |
| EPS | -1.54 |
| Moving Average 50 Days | 6.97 |
| Moving Average 200 Days | 7.42 |
| Change | 0.36 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $243.13 as of February 04, 2025 at a share price of $7.61. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $667.54 as of February 04, 2025 at a share price of $7.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
GlobeNewswire Inc.
Jan 07, 2025 2:15 PM GMT
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a potential best-in-class LSD1 inhibitor, is
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2025 1:30 PM GMT
Salt Lake City, UT, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announces that co-founder and CEO Chris Gibson, PhD will present at the upco
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
GlobeNewswire Inc.
Dec 20, 2024 9:05 PM GMT
Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 20